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Background: It was recently reported that the mono-iodoacetate (MIA) experimental model of osteoarthritis (OA)
courses with changes of neurons innervating the affected joints that are commonly interpreted as a neuronal
response to axonal injury. To better characterize these changes, we evaluated the expression of two markers of
neuronal damage, ATF-3 and NPY, and the growth associated protein GAP-43, in primary afferent neurons of OA
animals injected with three different doses of MIA (0.3, 1 or 2 mg). Measurements were performed at days 3, 7, 14,
21 and 31 post-MIA injection.
Results: OA animals showed the characteristic histopathological changes of the joints and the accompanying
nociceptive behaviour, evaluated by the Knee-Bed and CatWalk tests. An increase of ATF-3 expression was detected
in the DRG of OA animals as early as 3 days after the injection of 1 or 2 mg of MIA and 7 days after the injection of
0.3 mg. NPY expression was increased in animals injected with 1 or 2 mg of MIA, at day 3 or in all time-points,
respectively. From day 7 onwards there was a massive increase of GAP-43 expression in ATF-3 cells.
Conclusions: The expression of the neuronal injury markers ATF-3 and NPY as well as an up-regulation of GAP-43
expression, indicative of peripheral fibre regeneration, suggests that axonal injury and a regeneration response may
be happening in this model of OA. This opens new perspectives in the unravelling of the physiopathology of the
human disease.
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Osteoarthritis (OA) is a chronic degenerative joint dis-
order that affects a large proportion of the population,
being the most common type of articular disorders.
Patients’ major clinical manifestation is chronic pain that
typically worsens with weight bearing and activity or
movement of the affected joint [1]. Joint pain results
from the activation of primary afferent nerve fibres at
the joint, but the exact mechanisms of pain in OA re-
main inadequately understood [2,3].
Several studies in animal models of OA have been per-
formed to unravel the nociceptive mechanisms in this
pathology. The experimental model most commonly used
is the intra-articular injection of the metabolic inhibitor* Correspondence: jogomes@med.up.pt
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distribution, and reproduction in any mediummono-iodoacetate (MIA) into the knee joint of the rat.
This compound inhibits the activity of glyceraldehyde-3-
phosphate dehydrogenase of articular chondrocytes, lead-
ing to disruption of glycolytic energy metabolism and syn-
thetic processes and eventually to cell death [4,5]. Hence,
a progressive loss of articular cartilage and lesions of the
subchondral bone are observed in this model, which have
been described as closely resembling those observed in
OA patients [4].
A marker of neuronal damage, ATF-3, has been shown
in dorsal root ganglia (DRG) neurons, 8 and 14 days
post-MIA injection [6]. Moreover, we observed an in-
crease in CGRP in DRG cells 31 days after MIA injec-
tion, which occurred mainly in the medium and large
cell size population that in control animals did not ex-
press this peptide [7]. This phenomenon could result
from a phenotypic switch of these cells to assume char-
acteristics of nociceptors, or from a hypertrophy of smallCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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an alteration of the total cell size distribution pattern
was also observed [7]. Notwithstanding, both phenom-
ena have been described as a neuronal response to
axonal injury [8-11]. Furthermore, we also observed a
reduced retrograde labelling of Fluorogold in DRG neu-
rons of OA animals following injection of the tracer into
the affected knee, which could be due to axonal loss or
retraction, or another form of injury of the nerve term-
inals [7]. These data raise the question of a possible
damage of the joint afferents that would provoke
changes in the soma of these neurons, at the DRG level,
that resemble those occurring during a peripheral
neuropathy.
To better understand and characterize the possible oc-
currence of neuronal injury in the MIA model of OA,
we evaluated the expression of ATF-3 and NPY in DRG
neurons at different time-points of disease progression,
from 3 days after MIA injection until 31 days. ATF-3 is
a transcription factor that, as previously mentioned, has
been considered a marker of neuronal damage since it is
elevated in the DRG neurons following peripheral axonal
injury [12,13]. Similarly, NPY is a neurotransmitter that
under normal conditions is barely detected in DRG neu-
rons [14,15], but peripheral nerve injury induces its ex-
pression in their cell bodies [16,17]. Additionally, we
investigated whether a regeneration process wasFigure 1 Histopathology of knee sections of OA animals. Rats received
and were sacrificed at 3 (A, F, K), 7 (B, G, L), 14 (C, H, M), 21 (D, I, N) and 31
of a group of 5 animals. The sections were stained with Safranin-O that sta
stains bone. Histopathological alterations, namely decrease in proteoglycan
the thickness of the articular cartilage, erosion of the hyaline articular cartila
time-dependent. C indicates cartilage; SB, subchondral bone; M, meniscus.occurring as part of a neuronal response to a hypothet-
ical injury of peripheral nerves. The growth-associated
protein GAP-43 served that purpose since its expression
is up-regulated in regenerating peripheral fibres [18-20].
Finally, since there is a correlation between MIA con-
centration and the degree of sensitization of afferent
nerve fibres [21], three different doses of MIA were used
in this study in order to investigate whether the
observed effects were dose-dependent.
Results
Histological analysis of the knee joint
No damage of the knee joint could be observed in
saline-injected control animals at all time-points studied
(data not shown). In contrast, the histopathological find-
ings observed in OA animals were dose and time-
dependent. At day 3, no alteration or a minimal decrease
in the proteoglycan staining was observed in animals
injected with 0.3 mg of MIA, resulting in a slight de-
crease of Safranin-O staining (Figure 1A). This became
more apparent at day 14, when some irregularity in the
superficial zone of the articular cartilage was observed
(Figure 1C). At day 21, chondrocyte death and loss of
intercellular matrix was observed (Figure 1D), and this
was more pronounced and accompanied by a marked
decrease of the thickness of the articular cartilage at day
31 (Figure 1E).an intra-articular injection of 0.3 (A-E), 1 (F-J) or 2 mg (K-O) of MIA
days (E, J, O) post-MIA injection. Each rat knee image is representative
ined cartilage and its proteoglycan content and Fast Green, which
staining, chondrocyte death, loss of intercellular matrix, decrease of
ge and exposure of the subcondral bone, were dose and
Scale bar: 200 μm.
Figure 3 Evolution of the percentage of the ipsilateral
paw-print total intensity, assessed in the CatWalk test, of
animals injected with saline (control; n = 5) or 0.3, 1 or 2 mg of
MIA (OA; n = 25/group) on various days after the injection until
the day of sacrifice (3, 7, 14, 21, 31). At each sacrifice time-point,
5 animals per group were euthanized. Baseline score was
determined for all animals prior to injection (day 0). * P < 0.05,
*** P< 0.001 significantly different from baseline values for the 0.3 mg
dose of MIA; # P< 0.05, ## P< 0.01, ### P<0.001 significantly different
from baseline values for the 1 mg dose of MIA; } P<0.05, }}} P<0.001
significantly different from baseline values for the 2 mg dose of MIA
(Repeated Measures ANOVA followed by LSD post-hoc test).
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observed at day 3 in animals injected with 1 mg of MIA,
becoming more pronounced at day 7 (Figure 1F-G). At
day 14, some chondrocyte death and loss of matrix led
to decreased thickness of the articular cartilage, that was
more evident at day 21 (Figure 1H-I). At day 31, the ar-
ticular surface showed fissures and subchondral bone
become exposed (Figure 1J).
With the higher dose of MIA (2 mg), proteoglycan
staining loss from the extracellular matrix of the articu-
lar cartilage was more pronounced at day 3 than with
the lower doses (Figure 1K). Moreover, chondrocyte
death was already apparent at day 7, and at day 14 there
was a marked loss of extracellular matrix and a decrease
of the thickness of the articular cartilage, which pre-
sented some fissures (Figure 1L-M). A complete erosion
of the hyaline articular cartilage and exposure of the
subcondral bone was observed at day 21, while thicken-
ing of the subchondral bone was apparent at day 31
(Figure 1N-O).
Behavioural testing
Knee-Bend and CatWalk tests were used to evaluate the
movement-induced nociception caused by different
doses of MIA. Overall, changes in nociception were
concentration- and time-dependent (Figures 2 and 3).
Knee-Bend scores of saline-injected control animals
were similar to those observed at baseline in all time-
points studied. When compared to the baseline valuesFigure 2 Evolution of the Knee-Bend score of animals injected
with saline (control; n = 5) or 0.3, 1 or 2 mg of MIA (OA; n = 25/
group) on various days after the injection until the day of
sacrifice (3, 7, 14, 21, 31). At each sacrifice time-point 5 animals
per group were euthanized. Baseline score was determined for all
animals prior to the injection (day 0). * P < 0.05, ** P < 0.01,
*** P < 0.001 significantly different from baseline values for the
0.3 mg dose of MIA; ## P < 0.01, ### P< 0.001 significantly different
from baseline values for the 1 mg dose of MIA; } P < 0.05, }} P < 0.01,
}}} P < 0.001 significantly different from baseline values for the 2 mg
dose of MIA (Repeated Measures ANOVA followed by LSD post-hoc
test).and to the control animals, an increase in the Knee-
Bend score was evident as early as day 3 post-injection
for the 3 concentrations of MIA (Figure 2). The animals
receiving 0.3 mg of MIA showed the lowest Knee-Bend
score. The score, which was significantly higher than
baseline levels at all time-points studied (P<0.05;
Figure 2), was increased at day 3, slightly reducing from
then until day 17, when it started to increase again.
Animals receiving 1 or 2 mg of MIA showed a similar
high Knee-Bend score at day 3 (Figure 2). After this ini-
tial phase of disease progression, Knee-Bend scores of
animals injected with 2 mg were higher than those of
animals injected with 1 mg, while at latter stages no dif-
ferences were observed. In fact, the Knee-Bend scores of
animals injected with 1 mg of MIA showed an evolution
pattern similar to that observed with the 0.3 mg con-
centration (Figure 2), with a marked increase at day 3,
reducing from that time-point till day 13, and a fur-
ther increase at day 17, reaching values similar to day
3 from day 24 onwards. The evolution pattern of the
animals injected with 2 mg of MIA was smoother, re-
ducing very slightly after day 3 and returning to these
levels from day 24 onwards (Figure 2). At day 31, ani-
mals receiving the three different doses showed similar
Knee-Bend scores.
The percentage of ipsilateral paw-print intensity, as
measured by the CatWalk test, followed a pattern that
was also concentration- and time-dependent (Figure 3).
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decrease in the ipsilateral paw-print intensity. At most
time-points, the ipsilateral paw-print intensity of these
animals were significantly below baseline levels and
below levels of control animals, being not significantly
different from baseline values only at days 17 and 24
(Figure 3). Animals injected with 1 or 2 mg of MIA
showed a reduced ipsilateral paw-print intensity signifi-
cantly different from baseline levels and from control
animals at all time-points evaluated (P<0.05; Figure 3),
which was more pronounced in the animals injected
with 2 mg (with the exception of day 24 that was not
significantly different for this dose).
The temporal profile observed in the CatWalk test was
similar for the three MIA doses. There was an initial de-
crease in the ipsilateral paw-print intensity at day 3, fol-
lowed by a slight increase until days 13–17, decreasing
thereafter. At day 31, the ipsilateral paw-print intensity
observed was similar for the OA animals injected with
the different MIA doses (Figure 3).
No differences in the ipsilateral paw-print intensity
were observed in the saline-injected animals throughout
the study.
Immunohistochemistry
The number of neurons expressing ATF-3 and NPY was
analysed in animals injected with saline and with 0.3, 1
or 2 mg of MIA, at days 3, 7, 14, 21 and 31 post-injec-
tion. FG was injected in all animals 7 days prior to sacri-
fice. Because both ATF-3 and NPY expression was
observed in both FG positive and FG negative cells, and
since, as already mentioned, a reduced retrogradeFigure 4 ATF-3 expression in L3, L4 and L5 ipsilateral DRG. Animals re
MIA (OA) and were sacrificed at 3, 7, 14, 21 and 31 days post-injection. A a
ATF-3 from control rats (A) and rats injected with 2 mg of MIA (B) sacrifice
(Mann–Whitney test).labelling of FG in the DRG of OA animals was observed
[7], we chose to show the numerical data as the total
number of neurons expressing ATF-3 or NPY per sec-
tion rather than the percentage of FG labelled cells that
were immunopositive. The temporal profile and dose-
related expression was different for the two markers
evaluated (Figures 4C and 5C).
The expression of GAP-43 was evaluated in ATF-3
positive cells, in animals injected with saline and
with 2 mg of MIA, at days 3, 7, 14 and 21 post-injection
(Figures 6). Since at 31 days ATF-3 expression in the
2 mg group of animals is at baseline levels, this time-
point was excluded in this analysis.
Expression of ATF-3 in DRGs during MIA-induced OA
Baseline ATF-3 expression was similar in control ani-
mals at all time-points studied in both the ipsilateral and
contralateral DRG, as well as in the contralateral DRG
of OA animals. There was an increase of the number of
neurons expressing ATF-3 in ipsilateral DRG of MIA-
injected animals, which was dose and time-dependent
(Figure 4). At day 3, no changes were observed in ani-
mals injected with 0.3 mg of MIA, but at day 7 there
was an upregulation of the number of neurons expres-
sing ATF-3 in the DRG (P<0.05; Figure 4). This upregu-
lation was maintained at day 14, increasing further at
days 21 and 31.
Animals injected with 1 mg of MIA showed an in-
crease of the number of neurons expressing ATF-3 sig-
nificantly different from control animals as early as day
3 (from 0.8 ± 0.1 cells/section in control animals to
2.4 ± 0.4 cells/section in OA animals; P<0.01). Theceived an intra-articular injection of saline (control) or 0.3, 1 or 2 mg of
nd B are images representative of immunofluorescence reactions for
d at 7 days. * P < 0.05, ** P < 0.01 significantly different from controls
Figure 5 NPY expression in L3, L4 and L5 ipsilateral DRG. Animals received an intra-articular injection of saline (control) or 0.3, 1 or 2 mg of
MIA (OA) and were sacrificed at 3, 7, 14, 21 and 31 days post-injection. A and B are images representative of immunofluorescence reactions for
NPY from control rats (A) and rats injected with 2 mg of MIA (B) sacrificed at 7 days. * P < 0.05, ** P < 0.01 significantly different from controls
(Mann–Whitney test).
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until day 14, increasing again at day 21. At day 31, the
number of neurons expressing ATF-3 decreased again,
though it was significantly higher than the baseline ex-
pression observed in control animals (P<0.01; Figure 4).
The dose of 2 mg of MIA induced a marked increase
in the number of neurons expressing ATF-3 at day 3
(from 0.8 ± 0.1 cells/section in control animals to
4.8 ± 0.9 cells/section in OA animals; P<0.01). ThisFigure 6 GAP-43 expression in ATF-3 positive cells in L3, L4 and L5 ip
(control) or 2 mg of MIA (OA) and were sacrificed at 3, 7, 14 and 21 days p
immunofluorescence reactions for ATF-3 plus GAP-43 in sections of ipsilate
sacrificed at 7 days. .upregulation was maintained at day 7, decreasing signifi-
cantly to baseline levels at day 14. At day 21, a further
increase of the number of neurons expressing ATF-3
was observed (2.9 ± 0.7 ATF-3 positive cells/section),
significantly different from control animals (P<0.05;
Figure 4). At day 31, the number of neurons expres-
sing ATF-3 returned again to baseline levels.
The number of neurons expressing ATF-3 was higher
with the 2 mg dose of MIA, therefore evaluation of cellsilateral DRG. Animals received an intra-articular injection of saline
ost-injection. A and B are images representative of
ral DRG from control rats (A) and rats injected with 2 mg of MIA (B)
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pression was observed across all neuronal size ranges
(Figure 7). At 3 and 7 days the expression followed the
normal distribution pattern, but at day 14, when there
was a decrease of the number of neurons expressing
ATF-3, it was as a consequence of decreased expression
in small and medium size cells (Figure 7).
Expression of NPY in DRGs during MIA-induced OA
Similarly to ATF-3 expression, the increase of NPY ex-
pression profile was dose and time-dependent (Figure 5).
A very low baseline expression was observed in control
animals at all time-points studied, and in the contralat-
eral DRG of OA animals (data not shown). In the ani-
mals injected with 0.3 mg of MIA, the number of
neurons expressing NPY in the ipsilateral DRG was at
baseline levels at day 3. Thereafter, a slight increase of
the number of neurons expressing NPY occurred until
days 14 and 21, decreasing again at day 31. Nevertheless,
none of these very modest differences reached statistical
significance (Figure 5).
Conversely, an increase in the number of neurons
expressing NPY was observed at day 3 in the animals
injected with 1 mg of MIA (from 0.1 ± 0.0 cells/section
in control animals to 0.5 ± 0.1 cells/section in OA ani-
mals; P<0.01). The number of neurons expressing NPY
maintained thereafter, returning to baseline levels at
31 days (Figure 5).
The dose of 2 mg of MIA induced a significant in-
crease of the number of neurons expressing NPY imme-
diately at day 3, which was more striking at day 7 (with
5.0 ± 2.1 cells/section; P<0.01; Figure 5). At day 14, the
number of NPY cells were similar to that observed at
day 3, remaining sustained at day 21. At day 31, the
number of neurons expressing NPY was similar to con-
trol animals.
As for ATF-3 expression, NPY expression was
observed across all neuronal size range and at all time-
points followed the normal distribution pattern (data
not shown).
Correlation between ATF-3 and NPY with behavioural
data during MIA-induced OA
In an attempt to identify a possible correlation between
behaviour and the markers of neuronal damage studied,
a Pearson’s correlation coefficient was calculated for all
time-points and doses studied. Occasional isolated para-
meters show significant correlation but overall no sig-
nificant correlation was found between the parameters.
Expression of GAP-43, in ATF-3 positive cells, in DRGs
during MIA-induced OA
The number of neurons expressing ATF-3 was similar in
single and double immunohistochemistry reactions(Figures 4 and 6). Control animals showed a very low
baseline number of neurons expressing ATF-3, an aver-
age of 0.4 cells/section, and of this between 33-47%
of ATF-3 positive cells were also immunoreactive for
GAP-43 (0.1 ± 0.02 cells/section to 0.3 ± 0.02 cells/sec-
tion) (Figure 6).
In OA animals injected with 2 mg of MIA, at 3 days
post-injection of the 4.0 ± 1.2 ATF-3 cells/section, 34%
were also GAP-43 positive (1.4 ± 0.6 ATF-3 +GAP43
cells/section; Figure 6), a percentage similar to that of
controls. However, at day 7, of the 4.8 ± 1.6 ATF-3 cells/
section, 3.6 ± 1.3 were also GAP-43 positive, which cor-
responds to 75% of the total ATF-3 cells. This percent-
age was very similar at 14 days (71%) and at 21 days
(76%), despite the oscillations of the ATF-3 expression,
due to the biphasic pattern observed (Figure 6).
Analysis of cell size distribution showed that ATF-3
cells that are GAP-43 positive followed the same pattern
as total ATF-3 cells (Figure 7).
Discussion
Animal models are important and essential tools to un-
ravel the molecular mechanisms of pain in OA and for
pre-clinical testing of new therapies. The MIA model
has been widely used in pain associated studies and to
test potential analgesic agents, since it is a rapid and eas-
ily reproducible method, and has been described as the
one that best mimics the histopathology of human OA
[22-26]. The severity of the MIA-induced OA has been
shown to be concentration and time-dependent in a
range of concentrations [22,26,27]. Upon evaluation of
the histopathology profile with different doses across a
time period of 31 days, we observed a pattern of lesions
clearly dependent of MIA concentration. Behavioural
findings also showed a dose and time-dependent pattern
on nociception, when evaluated by the Knee-Bend and
CatWalk tests. Moreover, the ipsilateral paw-print inten-
sity profile here observed with the three doses of MIA
was comparable to the weight bearing evaluation
described by Pomonis et al. [26] using similar doses.
Neuronal hypertrophy and phenotypic alterations in
animals injected with 2 mg of MIA [7], along with data
revealing ATF-3 expression in DRG neurons of animals
with MIA-induced OA [6], suggested that neuronal
damage might be occurring in this experimental model.
In the present study, we further evaluated this possibility
by investigating the expression of two widely used neur-
onal injury markers, ATF3 and NPY, in the DRG neu-
rons, at different time-points of the OA evolution and
using different doses of MIA.
The presence of ATF-3 has been reported in L5 DRG
neurons of OA animals injected with 1 mg of MIA at
day 8 and 14 [6]. In another study ATF-3 expression has
been reported in FG labelled L4 DRG neurons of OA
Figure 7 ATF-3 and GAP-43 plus ATF-3 expression per neuronal perikaria cross-sectional area range of control and 2 mg of MIA OA
animals. The DRGs were evaluated at 3, 7, 14 and 21 days post-injection.
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wards [28]. However, in the present study, we observed
ATF-3 expression in L3, L4 and L5 DRG as early as
3 days post-MIA injection, at doses routinely used to in-
duce OA (1 and 2 mg). Moreover, ATF-3 expression was
dose and time-dependent, with a biphasic pattern, andoccurred in various sized neurons as previously
described in axotomized DRG neurons [13].
ATF-3 has been described by several authors as a sen-
sitive marker of nerve damage [12,13]. This transcription
factor, barely present in the DRG of naive animals, is
dramatically induced in DRG neurons following
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ATF-3 seems to be a cellular response to some types of
stress, and nociceptive stimuli without nerve injury does
not seem to induce ATF-3 in sensory neurons [12,13].
This has been corroborated in studies where sciatic
nerve transection induced strong ATF-3 expression,
while intra-plantar inflammation induced by Complete
Freund’s Adjuvant did not [12,13]. As Braz and Basbaum
[12] stress, ATF-3 expression is not triggered only by the
increased activity of sensory fibres due to the lesion,
nerve damage being mandatory for such expression. In
MIA-induced OA there is no damage of the nerve per
se, but there might be injury of nerve endings located at
the joint that trigger a similar response but at a smaller
scale. Similarly, intraplantar injection of formalin, caus-
ing not only tissue inflammation but also injury of local
nerve endings, causes ATF-3 expression in some neu-
rons [13]. Also, Hill et al. [29] reported that skin incision
without real nerve damage induces nerve injury-like
responses such as ATF-3 expression.
ATF-3 is also expressed in the DRG neurons in
collagen-induced arthritis [30] and in monoarthritis fol-
lowing complete Freund´s adjuvant injection in the
tibiotarsal joint [31]. A possible role of positive regula-
tory factors, such as tumour necrosis factor α (TNF-α)
present in the neuroinflammatory environment, could
account for the activation of ATF-3 in those conditions,
as previously suggested by others [29,32]. However, it
should be noted that in collagen-induced arthritis ATF-3
expression was not affected by anti-TNF therapy [30].
Furthermore, bone destruction occurs in both models
[33,34] and in CFA induced arthritis there is a highly
significant correlation between pain behaviour and joint
destruction [34].
NPY expression in DRG neurons is evoked by injury
to sensory neurons [16,17,35], therefore, expression of
NPY was also evaluated in the present study. NPY has
been described to contribute to the excitability of axoto-
mized sensory neurons, which in turn could invoke ab-
errant spontaneous activity in damaged sensory nerves
that contribute to neuropathic pain [35,36]. Further-
more, it has been suggested that NPY can be released
intraganglionically, especially after peripheral nerve in-
jury, and act as a mediator of chemical cell-to-cell sig-
nalling [15]. Conversely, painful inflammation of rats’
hind paw does not induce NPY expression in DRG neu-
rons [37,38]. In our study, NPY expression was induced
by 1 or 2 mg of MIA immediately at day 3. From day 3
forward, NPY expression was only significantly different
from controls with the 2 mg dose, while the lowest dose
used (0.3 mg) never induced sufficient NPY expression
to reach statistical significance.
The temporal profile and dose related expression was
different for the two markers evaluated in this study,which may be due to different activation mechanisms. In
fact, while ATF-3 expression is a transcription factor
that may be elicited immediately in DRG neurons, NPY
expression might need more time since it could be
dependent of sympathetic-sensory coupling within the
DRG [39].
Interestingly, a biphasic pattern was observed both on
behavioural data and on the expression of the injury
related molecules, though no significant correlation be-
tween them was found.
Injury due to mechanical activation of the primary af-
ferent endings present in subcondral bone has been pro-
posed as one of the important mechanisms for the
generation of pain in OA [40-42]. Considering that ATF-
3 and NPY expression are signalling neuronal injury,
that could explain the second wave of increased expres-
sion of ATF-3 and NPY observed in the present study at
latter time points of the disease, when erosion of the
cartilage and exposure of subcondral bone occurs. The
absence of articular cartilage leads to bone-to-bone ar-
ticulation and exposure of nociceptor endings in the
bone to biomechanical forces associated with weight
bearing [42]. However, both neuronal injury markers
showed increased expression at day 3 with the higher
doses of MIA. Day 3 corresponds to an initial phase of
the disease when an inflammatory component has been
described by some authors [22,23,26], and no degener-
ation of the cartilage is present, even with the dose of
2 mg, as observed in the histopathological analysis. A
possible explanation for the increased expression of
ATF-3 and NPY at this early time point could be an in-
jury to nerve endings in the capsule and synovium. As
mentioned above, some authors propose that the neu-
roinflammatory environment could be the trigger to this
increased expression [29,31,32], but another possibility is
that MIA itself may cause a chemical injury of nerve
terminals in the injected knee. In fact, MIA is an inhibi-
tor of glicolysis that ultimately leads to the necrosis of
chondrocytes, but is not cell specific, and depending on
the concentration used different degrees of cell death
can be achieved. Actually, we observe that increasing
doses of MIA induce the expression of ATF-3 and NPY
in further neurons, which suggests that the chemical
stimuli might induce some axonal damage producing a
nerve-injury like response. In what concerns the reduc-
tion in ATF3- and NPY-expressing neurons in some
time-points, the possibility of loss of knee-joint afferent
neurons does not seem to explain it, since in our previ-
ous study [7] we did not observed a reduced number of
neurons in DRG of MIA injected animals, when total
counts were performed at 31 days.
The lack of correlation between neuropathic markers
and pain behaviours previously referred, indicate that
although a nerve injury may be important for pain
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tribute for nociception. In this context, the inflamma-
tory component is likely to cause a rise in the activation
of joint nociceptors, that in turn lead to an increased
sensitivity of spinal cord neurons, resulting in enhanced
nociception.
After peripheral axonal injury, the perikaria of affected
neurons and the surrounding glial cells respond to the
insult with morphological, metabolic and biochemical
changes [43], in order to promote survival and regener-
ation of the lesioned nerves [44]. ATF-3, besides being
implicated in cell death, may also have a role in inhib-
ition of apoptosis and induction of neurite elongation,
and thus promote neuronal survival, depending on the
stress signal, cell type and intracellular pathway activated
[45]. In fact, in the oncology field, where ATF-3 has
been extensively studied, it seems that the cellular con-
text strongly influences its role in cancer development,
acting as an oncogene or as a tumour suppressor [46].
Actually, it is possible that the fluctuation of ATF-3 over
time has to do with the trigger signal, and also derives
from the fact that ATF-3 expression is transient and reg-
ulates the balance between proliferative and apoptotic
signals.
On the other hand, GAP-43 expression seems to peak
when axons are elongating [47]. Therefore, GAP-43 ex-
pression was analysed in order to evaluate whether an
enhanced growth state had been activated. An increased
expression of GAP-43 in ATF-3 positive neurons was
observed immediately at day 3, but that became more
pronounced from day 7 onwards. The distance of the
axotomy site from the cell body seems to be important
in determining GAP-43 expression and the speed of its
up-regulation [18,48,49]. This could explain the delayed
expression in OA animals, since the damage is far from
the cell body. It should also be noted that GAP-43 was
expressed in all cell size DRG cells, as occurs after per-
ipheral axotomy [18]. The augmented expression of
GAP-43 reinforces the hypothesis of nerve damage.
ATF-3 along with other factors might be involved in the
fate of these neurons after injury [13], and in some cases
it might be having pro-survival, axonal-regeneration
effect.
Conclusions
In summary, MIA injection evokes dose-dependent ex-
pression of neuronal injury markers in DRG neurons, as
well as a regeneration protein expression, indicating that
axonal injury and a regeneration response may be hap-
pening in this model of OA. Two different phases were
observed. In the initial days, a chemically-induced neur-
opathy may be occurring, possibly with the contribution
of an inflammatory component, while at latter stages the
mechanical activation of exposed primary afferents couldbe involved, but additional experiments are required to
provide further evidence of this hypotheses. Actually, a
neuropathic component in human OA has also been
suggested [50-52]. Finally, correlation between this OA
model and human disease must be cautious, because
Barve et al. [53] analyzed and compared the transcrip-
tional profile generated in OA rats induced by MIA with




Adult male Wistar rats (Charles River, France) weighing
230 ± 20 g were used in this study. Animals were housed
in solid bottom cages, with water and food ad libitum,
and animal room was kept at a constant temperature of
22 °C and controlled lighting (12 h light/12 h dark
cycle).
All experimental procedures were performed in ac-
cordance with the ethical guidelines for the study of ex-
perimental pain in conscious animals [54], as well as the
European Communities Council Directive 86/609/EEC,
with all adequate measures being taken to minimise pain
or discomfort of the animals.
Induction of osteoarthritis
Under brief isoflurane anaesthesia, animals were injected
intra-articularly with 0.3, 1 or 2 mg of MIA (Sigma-
Aldrich, USA) dissolved in 25 μl of saline, or with only
25 μl of saline (controls). The syringe was inserted
through the patellar ligament into the intra-articular
joint space of the left knee. Animals were randomly
assigned to each group (n = 5/experimental group).
Behavioural testing
Nociception was evaluated in all animals by the Knee-
Bend and CatWalk tests as previously described [55].
Testing was performed blind at days 0, 3, 6, 10, 13, 17,
20, 24, 27 and 31 post-injection. However, the number
of animals in the behavioural assessment was not the
same at the different time-points, since animals were
pulled out at each sacrifice time-point resulting in a pro-
gressively decreasing number of animals, up to a mini-
mum of 5 animals per group at day 31. Briefly, the
Knee-Bend test consists on the recording of the squeaks
and/or struggle reactions in response to five flexions and
five extensions of the knee joint. The score of the test is
determined by the type of reaction to each movement of
the joint, according to the following evaluation scale: 0 -
no responses to any kind of extension or flexion of the
joint; 0.5 - struggle to maximal flexion/extension; 1 -
struggle to moderate flexion/extension and also vocaliza-
tions to maximal flexion/extension; 2 - squeak reactions
to moderate manipulations of the joint. The sum of the
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the Knee-Bend score, an indication of the animal’s
movement-induced nociception.
For the CatWalk test, animals were placed in a glass
platform illuminated such as to reflect light downwards
at the points of contact of the paw with the surface,
resulting in a bright sharp image of the paw-print. The
platform was monitored by a video camera placed under
the platform and connected to a computer equipped
with video acquisition software (Ulead Video Studio,
Corel Corporation, Canada). The intensity of the signal
depends on the area of the paw in contact with the plat-
form and increases with the pressure applied by the paw.
Image J 1.37 (www.tucows.com/preview/510562) was
used to analyse the images obtained from the videos
recorded during the animal evaluation. The number and
intensity of pixels above a defined threshold were quan-
tified, allowing the comparison of the area/pressure ap-
plied by each paw. Results were expressed in total
intensity of the ipsilateral hind paw as a percentage of
the total intensity of both hind paws. Therefore, as
alterations in the ipsilateral limb are in fact made up by
the contralateral hindlimb, the weight applied to the
contralateral paw may be inferred.
Tissue processing
Seven days prior to the end of the experiments 5 μl of
2% Fluorogold (FG) (Fluorochrome, Denver, CO, USA)
was injected intra-articularly in the left knee of the ani-
mals. This difference in the timing of FG injection was
done to ensure the same migration time of FG in all ani-
mals, but, as a consequence animals sacrificed at day 3
had the FG injection before the MIA injection, as
opposed to the others. At 3, 7, 14, 21 and 31 days after
saline or 0.3, 1 or 2 mg of MIA injection, animals were
anaesthetised and perfused with 4% paraformaldehyde
with 0.1% of picric acid. Their DRG from lumbar seg-
ments 3, 4 and 5 (L3, L4 and L5) were dissected, post-
fixed for 4 hours in the same fixative and kept in 30%
sucrose with 0.01% sodium azide. DRG were serially
sliced in 12 μm sections using a cryostat (Microm Inter-
national GmbH, Germany), and every 10th section was
collected in the same glass slide (8–10 sections from
each DRG, on average). DRGs were oriented to ensure
that longitudinal sections were made, and the number of
sections obtained from each DRG was similar between
animals, giving an indirect measure of this consistency.
The cutting process was always performed by the same
person and with the same method to ensure the
consistency of the procedure throughout the study. The
injected knees were also dissected, post-fixed for 72
hours and then decalcified for 8 hours in a buffer con-
taining 7% AlCl3, 5% formic acid and 8.5% HCl, as pre-
viously described [55]. The joints were then washed in0.1 M phosphate buffer saline (PBS) pH 7.2, and kept in
30% sucrose with 0.01% sodium azide until they were
cut in 20 μm sections using the cryostat.Histological analysis of the knee joint
Knee joint sections were stained by the Fast Green and
Safranin-O method in order to evaluate the extent of the
histopathological lesions. Slides were mounted with
Eukitt (Kindler, Germany) and images acquired with an
Axioskop 40 microscope equipped with an AxioCam
MRc5 camera (Carl Zeiss MicroImaging).Immunohistochemistry
Slides containing every tenth section of L3, L4 and L5
DRG of animals injected with saline or 0.3, 1 and 2 mg of
MIA and sacrificed at 3, 7, 14, 21 and 31 days post-
injection were used for immunofluorescence reactions
for ATF-3 and NPY. Slides from animals injected with
2 mg of MIA were also used for double immunofluores-
cence reactions for ATF-3 and GAP-43 at the same time
points after MIA injection. The immunohistochemistry
reactions for each marker were performed in adjacent
sections. DRG sections were rinsed in 0.1 M PBS pH 7.4,
followed by PBS + 0.3% triton-X (PBST), and incubated
in 10% normal serum in PBST for 90 min. Sections were
then incubated overnight at room temperature with one
of the following antibodies: rabbit anti-ATF-3 (1:500,
Santa Cruz Biotechnology Inc, USA); rabbit anti-NPY
(1:2000, Sigma-Aldrich, EUA). For double immunofluor-
escence reactions, sections were incubated overnight at
room temperature with the antibodies rabbit anti-ATF-3
(1:500, Santa Cruz Biotechnology Inc, USA) and mouse
anti-GAP-43 (1:500, Chemicon, EUA). After thorough
PBST washing, sections were incubated with Alexa-Fluor
568 donkey anti-rabbit secondary antibody (1:1000, Mo-
lecular Probes, USA) 1 h at room temperature. For
double immunofluorescence reactions, sections were
incubated with Alexa-Fluor 488 donkey anti-rabbit and
Alexa-Fluor 568 donkey anti-mouse secondary anti-
bodies (1:1000, Molecular Probes, USA) 1 h at room
temperature. Slides were then rinsed in PBST followed
by PBS, mounted with Prolong Gold Antifade medium
(Molecular Probes, USA) and coverslipped. Negative
control immunohistochemistry reactions, where the pro-
cedure was the same with the exception of the absence of
the primary antibodies, were performed to test for the
specificity of the primary antibodies. Slides were viewed
using a Zeiss Imager.Z1 fluorescence microscope (Carl
Zeiss MicroImaging GmbH, Germany) and all neurons
were identified based on morphological criteria and, in
the ATF-3 reaction, counted as positively labelled only if
the immunostained nucleus was clearly darker than the
surrounding cytoplasm. Countings were done blind as to
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menter to assure reproducibility.
Cell size distribution was determined in the animals
injected with 2 mg of MIA, by measuring their cross
sectional area.
Statistics
Results are presented as mean ± SEM. For behavioural
data, the temporal profile evaluation was analysed by
Repeated Measures ANOVA, followed by the Fisher's
least significant difference (LSD) post-hoc test. Immu-
nohistochemical data obtained from OA animals was
compared with data from control animals using the
Mann–Whitney test. A P value < 0.05 was accepted as
statistically significant.
To examine the correlation between the behavioural
measurements and ATF3 expression or NPY expression,
the Pearson’s correlation coefficient was calculated by
comparing the number of ATF3 or NPY in L3, L4 and
L5 DRGs versus the Knee-Bend score and the ipsilateral
paw print intensity measured by the CatWalk, at all
time-points and for the three MIA doses.
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